lp352
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
3
Phase 4
0
Earliest trial started Mar 3, 2022 (NCT05364021)
Timeline
Indications
Mechanism of action
HTR2C agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06908226 | Phase 3 | Feb 12, 2025 | Arena Pharmaceuticals |
| NCT06719141 | Phase 3 | Nov 11, 2024 | Arena Pharmaceuticals |
| NCT06660394 | Phase 3 | Oct 2, 2024 | Arena Pharmaceuticals |
| NCT05626634 | Phase 2 | Nov 8, 2022 | Arena Pharmaceuticals, University of Pennsylvania |
| NCT05364021 | Phase 1/Phase 2 (Phase 2) | Mar 3, 2022 | Arena Pharmaceuticals, University of Pennsylvania |
| NCT06149663 | N/A | — | Arena Pharmaceuticals |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arena Pharmaceuticals | For profit | 6 | 6 | 3 | 2022 |
| University of Pennsylvania | Academic/Hospital | 2 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1